U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H11ClFN5O3
Molecular Weight 303.6778
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLOFARABINE

SMILES

C([C@]1([H])[C@]([H])([C@@]([H])([C@]([H])(n2cnc3c(N)nc(Cl)nc32)O1)F)O)O

InChI

InChIKey=WDDPHFBMKLOVOX-AYQXTPAHSA-N
InChI=1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021673s024lbl.pdf

Clofarabine is a anti-cancer drug which was approved by FDA for the treatment of pediatric patients with relapsed or refractory acute lymphoblastic leukemia. After crossing the cell membrane the drug is rapidly metabolized by deoxycytidine kinase to diphosphate and triphosphate metabolites and these metabolites reversibly inhibit hRNR by binding to alpha subunit. Also the triphosphate is incorporated to DNA where it acts as a chain terminator.

CNS Activity

Curator's Comment:: Only a small amount of the drug was shown to cross the blood brain barrier in non-human primates.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CLOLAR

Approved Use

Clolar® (clofarabine) Injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.

Launch Date

1.10419195E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
308 ng/mL
40 mg/m² 1 times / day multiple, intravenous
dose: 40 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: CYTARABINE
CLOFARABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1793 ng × h/mL
40 mg/m² 1 times / day multiple, intravenous
dose: 40 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: CYTARABINE
CLOFARABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
28 ng × h/mL
40 mg/m² 1 times / day multiple, intravenous
dose: 40 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
CLOFARABINE blood
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.9 h
40 mg/m² 1 times / day multiple, intravenous
dose: 40 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: CYTARABINE
CLOFARABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.5 h
40 mg/m² 1 times / day multiple, intravenous
dose: 40 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
CLOFARABINE blood
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
55 mg/m2 1 times / day multiple, intravenous
Highest studied dose
Dose: 55 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 55 mg/m2, 1 times / day
Sources:
unhealthy, 42 years
n = 4
Health Status: unhealthy
Condition: acute leukemia
Age Group: 42 years
Sex: M+F
Population Size: 4
Sources:
Other AEs: Nausea, Diarrhea...
Other AEs:
Nausea (grade 1-2, 2 patients)
Diarrhea (grade 1, 3 patients)
Hepatotoxicity (grade 3, 2 patients)
Sources:
40 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 40 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg/m2, 1 times / day
Sources:
unhealthy, 42 years
n = 31
Health Status: unhealthy
Condition: acute leukemia
Age Group: 42 years
Sex: M+F
Population Size: 31
Sources:
Other AEs: Nausea, Fatigue...
Other AEs:
Nausea (grade 1-2, 3 patients)
Fatigue (grade 3, 1 patient)
Diarrhea (grade 1, 2 patients)
Cramp (grade 1, 1 patient)
Anorexia (grade 1, 1 patient)
Mucositis (grade 1, 1 patient)
Edema (grade 1, 1 patient)
Hepatotoxicity (grade 3-4, 4 patients)
Sources:
2 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 2 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / day
Sources:
unhealthy, 51 years
n = 6
Health Status: unhealthy
Condition: solid tumors
Age Group: 51 years
Sex: M+F
Population Size: 6
Sources:
DLT: Myelosuppression...
Dose limiting toxicities:
Myelosuppression (grade 3, 2 patients)
Sources:
6 mg 1 times / day multiple, oral
Highest studied dose
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, 60-76 years
n = 1
Health Status: unhealthy
Condition: Acute Myeloid Leukemia
Age Group: 60-76 years
Population Size: 1
Sources:
Other AEs: Nausea, Hypoalbuminemia...
Other AEs:
Nausea (grade 1-2, 1 patient)
Hypoalbuminemia (grade 1-2, 1 patient)
Blood bilirubin decreased (grade 1-2, 1 patient)
Lymphopenia (grade 3-4)
Sources:
70 mg/m2 1 times / day multiple, intravenous
Highest studied dose
Dose: 70 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 70 mg/m2, 1 times / day
Sources:
unhealthy, child
n = 2
Health Status: unhealthy
Condition: ALL
Age Group: child
Population Size: 2
Sources:
Other AEs: Hyperbilirubinemia, Vomiting...
Other AEs:
Hyperbilirubinemia (grade 4, 2 patients)
Vomiting (grade 2-3, 2 patients)
Maculopapular rash (grade 3, 2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Diarrhea grade 1, 3 patients
55 mg/m2 1 times / day multiple, intravenous
Highest studied dose
Dose: 55 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 55 mg/m2, 1 times / day
Sources:
unhealthy, 42 years
n = 4
Health Status: unhealthy
Condition: acute leukemia
Age Group: 42 years
Sex: M+F
Population Size: 4
Sources:
Nausea grade 1-2, 2 patients
55 mg/m2 1 times / day multiple, intravenous
Highest studied dose
Dose: 55 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 55 mg/m2, 1 times / day
Sources:
unhealthy, 42 years
n = 4
Health Status: unhealthy
Condition: acute leukemia
Age Group: 42 years
Sex: M+F
Population Size: 4
Sources:
Hepatotoxicity grade 3, 2 patients
55 mg/m2 1 times / day multiple, intravenous
Highest studied dose
Dose: 55 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 55 mg/m2, 1 times / day
Sources:
unhealthy, 42 years
n = 4
Health Status: unhealthy
Condition: acute leukemia
Age Group: 42 years
Sex: M+F
Population Size: 4
Sources:
Anorexia grade 1, 1 patient
40 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 40 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg/m2, 1 times / day
Sources:
unhealthy, 42 years
n = 31
Health Status: unhealthy
Condition: acute leukemia
Age Group: 42 years
Sex: M+F
Population Size: 31
Sources:
Cramp grade 1, 1 patient
40 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 40 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg/m2, 1 times / day
Sources:
unhealthy, 42 years
n = 31
Health Status: unhealthy
Condition: acute leukemia
Age Group: 42 years
Sex: M+F
Population Size: 31
Sources:
Edema grade 1, 1 patient
40 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 40 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg/m2, 1 times / day
Sources:
unhealthy, 42 years
n = 31
Health Status: unhealthy
Condition: acute leukemia
Age Group: 42 years
Sex: M+F
Population Size: 31
Sources:
Mucositis grade 1, 1 patient
40 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 40 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg/m2, 1 times / day
Sources:
unhealthy, 42 years
n = 31
Health Status: unhealthy
Condition: acute leukemia
Age Group: 42 years
Sex: M+F
Population Size: 31
Sources:
Diarrhea grade 1, 2 patients
40 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 40 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg/m2, 1 times / day
Sources:
unhealthy, 42 years
n = 31
Health Status: unhealthy
Condition: acute leukemia
Age Group: 42 years
Sex: M+F
Population Size: 31
Sources:
Nausea grade 1-2, 3 patients
40 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 40 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg/m2, 1 times / day
Sources:
unhealthy, 42 years
n = 31
Health Status: unhealthy
Condition: acute leukemia
Age Group: 42 years
Sex: M+F
Population Size: 31
Sources:
Fatigue grade 3, 1 patient
40 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 40 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg/m2, 1 times / day
Sources:
unhealthy, 42 years
n = 31
Health Status: unhealthy
Condition: acute leukemia
Age Group: 42 years
Sex: M+F
Population Size: 31
Sources:
Hepatotoxicity grade 3-4, 4 patients
40 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 40 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg/m2, 1 times / day
Sources:
unhealthy, 42 years
n = 31
Health Status: unhealthy
Condition: acute leukemia
Age Group: 42 years
Sex: M+F
Population Size: 31
Sources:
Myelosuppression grade 3, 2 patients
DLT
2 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 2 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / day
Sources:
unhealthy, 51 years
n = 6
Health Status: unhealthy
Condition: solid tumors
Age Group: 51 years
Sex: M+F
Population Size: 6
Sources:
Blood bilirubin decreased grade 1-2, 1 patient
6 mg 1 times / day multiple, oral
Highest studied dose
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, 60-76 years
n = 1
Health Status: unhealthy
Condition: Acute Myeloid Leukemia
Age Group: 60-76 years
Population Size: 1
Sources:
Hypoalbuminemia grade 1-2, 1 patient
6 mg 1 times / day multiple, oral
Highest studied dose
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, 60-76 years
n = 1
Health Status: unhealthy
Condition: Acute Myeloid Leukemia
Age Group: 60-76 years
Population Size: 1
Sources:
Nausea grade 1-2, 1 patient
6 mg 1 times / day multiple, oral
Highest studied dose
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, 60-76 years
n = 1
Health Status: unhealthy
Condition: Acute Myeloid Leukemia
Age Group: 60-76 years
Population Size: 1
Sources:
Lymphopenia grade 3-4
6 mg 1 times / day multiple, oral
Highest studied dose
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, 60-76 years
n = 1
Health Status: unhealthy
Condition: Acute Myeloid Leukemia
Age Group: 60-76 years
Population Size: 1
Sources:
Vomiting grade 2-3, 2 patients
70 mg/m2 1 times / day multiple, intravenous
Highest studied dose
Dose: 70 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 70 mg/m2, 1 times / day
Sources:
unhealthy, child
n = 2
Health Status: unhealthy
Condition: ALL
Age Group: child
Population Size: 2
Sources:
Maculopapular rash grade 3, 2 patients
70 mg/m2 1 times / day multiple, intravenous
Highest studied dose
Dose: 70 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 70 mg/m2, 1 times / day
Sources:
unhealthy, child
n = 2
Health Status: unhealthy
Condition: ALL
Age Group: child
Population Size: 2
Sources:
Hyperbilirubinemia grade 4, 2 patients
70 mg/m2 1 times / day multiple, intravenous
Highest studied dose
Dose: 70 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 70 mg/m2, 1 times / day
Sources:
unhealthy, child
n = 2
Health Status: unhealthy
Condition: ALL
Age Group: child
Population Size: 2
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate.
1991 May 1
Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome.
2004 Dec
New nucleoside analogs in the treatment of solid tumors.
2004 Jul-Aug
New nucleoside analogs in the treatment of hematological disorders.
2004 May-Jun
Bibliography. Current world literature. Therapeutic modalities.
2004 Nov
Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia.
2004 Nov
Clofarabine in adult acute leukemias: clinical success and pharmacokinetics.
2004 Oct
Nucleosides as anticancer agents: from concept to the clinic.
2005
Clofarabine: in pediatric patients with acute lymphoblastic leukemia.
2005
Biochemical modulation of cytarabine triphosphate by clofarabine.
2005 Apr
Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review.
2005 Dec
New drugs and dosage forms.
2005 Feb 1
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
2005 Feb 1
Gateways to clinical trials.
2005 Jun
The distribution, metabolism, and elimination of clofarabine in rats.
2005 Jun
Complete remission following clofarabine treatment in refractory juvenile myelomonocytic leukemia.
2005 Mar
Clofarabine.
2005 May
Clofarabine.
2005 May
The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog.
2005 May 15
New agents in the treatment of childhood leukemias and myelodysplastic syndromes.
2005 Nov
New agents for the treatment of acute myeloid leukemia.
2006
Treatment of older patients with acute myeloid leukemia--new agents.
2006 Apr
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
2006 Apr 20
Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia.
2006 Dec
Nursing considerations for clofarabine in the treatment of acute lymphoblastic leukemia in children.
2006 Dec
New drugs 06, part I.
2006 Feb
Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment.
2006 Jul 1
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
2006 Jul 1
The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma.
2006 Nov
Clofarabine and nelarabine: two new purine nucleoside analogs.
2006 Nov
Gateways to clinical trials.
2006 Oct
A tale of two drugs.
2006 Oct
Discovery and development of clofarabine: a nucleoside analogue for treating cancer.
2006 Oct
Clofarabine: new drug. Children with acute lymphoblastic leukaemia: a last resort.
2007 Dec
Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine.
2007 Dec
Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants.
2007 Dec
Saccharomyces cerevisiae emboli in an immunocompromised patient with relapsed acute myeloid leukaemia.
2007 Jul
Comparison of fast liquid chromatography/tandem mass spectrometric methods for simultaneous determination of cladribine and clofarabine in mouse plasma.
2007 Jun 28
Advances in the management of AML in the elderly.
2007 Mar
Clofarabine: past, present, and future.
2007 Oct
Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemia.
2007 Sep
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.
2007 Sep 15
Synthetic studies on formamidopyrimidines related to clofarabine.
2008 Aug
Acute myeloid leukemia in the elderly.
2008 Aug
Clofarabine acts as radiosensitizer in vitro and in vivo by interfering with DNA damage response.
2008 Jan 1
Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia.
2008 Mar
Clofarabine in refractory Langerhans cell histiocytosis.
2008 Nov
Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues.
2008 Oct
Clofarabine: in search of combinations for the treatment of patients with high-risk acute myeloid leukemia.
2008 Oct 15
Enhancement of the in vivo antitumor activity of clofarabine by 1-beta-D-[4-thio-arabinofuranosyl]-cytosine.
2009 Jul
Patents

Patents

Sample Use Guides

The recommended pediatric dose is 52 mg/m2 given as an intravenous infusion over 2 hours daily for 5 consecutive days of a 28-day cycle. Repeat cycles every 2-6 week.
Route of Administration: Intravenous
HL-60 cells or HL/ara-C20 cells were incubated with different concentrations of clofarabine for 72 h. The 50%-growth-inhibitory concentration IC50 was 50 nM for HL60 and 320 nM for HL/ara-C20 cells.
Name Type Language
CLOFARABINE
EMA EPAR   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
CLOFARABINE [VANDF]
Common Name English
CLOFARABINE [MI]
Common Name English
CLOFARABINE [WHO-DD]
Common Name English
9H-PURIN-6-AMINE, 2-CHLORO-9-(2-DEOXY-2-FLUORO-.BETA.-D-ARABINOFURANOSYL)
Common Name English
CLOLAR
Brand Name English
CLOFARABINE [INN]
Common Name English
CLOFARABINE [ORANGE BOOK]
Common Name English
NSC-759857
Code English
CLOFARABINE [EMA EPAR]
Common Name English
CLOFARABINE [USAN]
Common Name English
CLOFARABINE [MART.]
Common Name English
EVOLTRA
Brand Name English
CLOFARABINE [JAN]
Common Name English
2-CHLORO-9-(2-DEOXY-2-FLUORO-.BETA.-D-ARABINOFURANOSYL)-9H-PURIN-6-AMINE
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 668118
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
NDF-RT N0000000233
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
FDA ORPHAN DRUG 153201
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
NCI_THESAURUS C1556
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
WHO-VATC QL01BB06
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
EMA ASSESSMENT REPORTS EVOLTRA (AUTHORIZED: PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA)
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
NDF-RT N0000175595
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
FDA ORPHAN DRUG 154802
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
LIVERTOX 219
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
WHO-ATC L01BB06
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
NCI_THESAURUS C2150
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
Code System Code Type Description
RXCUI
44151
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
PRIMARY RxNorm
FDA UNII
762RDY0Y2H
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
PRIMARY
EPA CompTox
123318-82-1
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
PRIMARY
DRUG BANK
DB00631
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
PRIMARY
ChEMBL
CHEMBL1750
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
PRIMARY
EU-Orphan Drug
EU/3/01/082(EXPIRED)
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
PRIMARY Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in May 2016 at the end of the period of market exclusivity. On 5 February 2002, orphan designation (EU/3/01/082) was granted by the European Commission to ILEX Services Limited, United Kingdom, for 2-chloro-9-[2-deoxy-2-fluoro-ß-D-arabinofuranosyl]adenine for the treatment of acute lymphoblastic leukaemia (ALL). The sponsorship was transferred to Bioenvision, United Kingdom, in December 2002 and subsequently to Genzyme Europe BV, The Netherlands, in May 2008. Update: 2-chloro-9-[2-deoxy-2-fluoro-ß-D-arabinofuranosyl]adenine has been authorised in the European Union as Evoltra since 29 May 2006.
INN
8422
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
PRIMARY
WIKIPEDIA
CLOFARABINE
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
PRIMARY
DRUG CENTRAL
691
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
PRIMARY
EVMPD
SUB21902
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
PRIMARY
MESH
C068329
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
PRIMARY
MERCK INDEX
M3636
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
PRIMARY Merck Index
IUPHAR
6802
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
PRIMARY
PUBCHEM
119182
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
PRIMARY
CAS
123318-82-1
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
PRIMARY
EU-Orphan Drug
EU/3/03/141(WITHDRAWN)
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
PRIMARY Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in July 2014 on request of the Sponsor. On 8 May 2003, orphan designation (EU/3/03/141) was granted by the European Commission to Bioenvision Limited, United Kingdom, for 2-chloro-9-[2-deoxy-2’-fluoro-ß-D-arabinofuranosyl]adenine for the treatment of acute myeloid leukaemia. The sponsorship was transferred to Genzyme Europe BV, The Netherlands, in May 2008.
NCI_THESAURUS
C26638
Created by admin on Fri Jun 25 22:06:49 UTC 2021 , Edited by admin on Fri Jun 25 22:06:49 UTC 2021
PRIMARY